期刊
SCIENTIFIC REPORTS
卷 8, 期 -, 页码 -出版社
NATURE PORTFOLIO
DOI: 10.1038/s41598-018-22690-2
关键词
-
资金
- Spanish Ministry of Economy and Competitiveness [BFU2012-31444, CTQ2010-19690]
- Junta de Comunidades Castilla-LaMancha
- Fondo Europeo de Desarrollo Regional (FEDER) [POII11-0159-0054]
- Comunidad de Madrid [S2010-BMD2308]
- Fundacion Tatiana Perez de Guzman el Bueno [Patrocinio 2013-001]
- Junta para la Ampliacion de Estudios
- Fondo Socio Europeo (FSE)
The key metabolic sensor adenosine monophosphate-dependent kinase (AMPK) has emerged as a promising therapeutic target for cancer prevention and treatment. Besides its role in energy homeostasis, AMPK blocks cell cycle, regulates autophagy and suppresses the anabolic processes required for rapid cell growth. AMPK is especially relevant in prostate cancer in which activation of lipogenic pathways correlate with tumor progression and aggressiveness. This study reports the discovery of a new series of 2-oxindole derivatives whose AMPK modulatory ability, as well as the antitumoral profile in prostate cancer cells, was evaluated. One of the assayed compounds, compound 8c, notably activated AMPK in cultured PC-3, DU145 and LNCaP prostate cancer cells. Likewise, compound 8c caused PC-3, DU145 and LNCaP cells viability inhibition. Selective knocking down of alpha 1 or alpha 2 isoforms as well as in vitro assays using human recombinant alpha 1 beta 1 gamma 1 or alpha 2 beta 1 gamma 1 AMPK isoforms revealed that compound 8c exhibit preference for AMPK alpha 1. Consistent with efficacy at the cellular level, compound 8c was potent in suppressing the growth of PC-3 xenograft tumors. In conclusion, our results show that a new 2-oxindole fluorinated derivative exerts potent in vivo antitumor actions against prostate cancer cells, indicating a promising clinical therapeutic strategy for the treatment of androgen-independent prostate cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据